Literature DB >> 3168396

The influence of verapamil and nifedipine on hepatic indocyanine green clearance in patients with HBsAg-positive cirrhosis and ascites.

C S Lay1, Y T Tsai, C W Kong, F Y Lee, T T Chang, H C Lin, C M Yang, S D Lee, B N Chiang, K J Lo.   

Abstract

The influence of verapamil and nifedipine on hepatic indocyanine green kinetics was studied in 12 patients with HBsAg-positive cirrhosis and ascites. Hepatic clearance and its two biologic determinants, hepatic blood flow and metabolic activity (intrinsic clearance [maximum velocity/metabolite elimination rate constant, or Vmax/km]), were determined from hepatic indocyanine green elimination at steady state in patients with cirrhosis. Acute intravenous administration 10 mg verapamil significantly increased the hepatic indocyanine green blood flow (p less than 0.05), but significantly decreased the hepatic clearance (p less than 0.05), extraction ratio (p less than 0.05) and Vmax/km (p less than 0.05). However, acute sublingual administration of 10 mg nifedipine resulted in no significant change in any parameters of hepatic elimination function. These results show that verapamil, but not nifedipine, might impair the transhepatic extraction activity of hepatocytes in patients with HBsAg-positive cirrhosis and ascites.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3168396     DOI: 10.1038/clpt.1988.179

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Effect of verapamil on nitric oxide synthase in a portal vein-ligated rat model: role of prostaglandin.

Authors:  Chii-Shyan Lay; C-M-Y May; Fa-Yauh Lee; Yang-Te Tsai; Shou-Dong Lee; Shu Chien; Shlomoh Sinchon
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

2.  Lack of effect of verapamil and isosorbide dinitrate on the hepatic clearance of indocyanine green in cirrhosis.

Authors:  C Merkel; M Bolognesi; P Angeli; G F Finucci; P Amodio; S Bellon; A Gatta
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 3.  Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.

Authors:  D J Morgan; A J McLean
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

4.  Exogenous adenosine 5'-triphosphate does not improve survival in rats with acute liver failure.

Authors:  Erin P Becker; DongFeng Sun; Gerald Y Minuk
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

Review 5.  Drug administration in chronic liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.228

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.